tbuckley/cabot-search huggingface dataset:
Clinical outcomes of patients with recurrent small cell lung cancer receiving third-line chemotherapy.
Authors: Koichi Saruwatari, Shigeki Umemura, Shogo Nomura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Yuichiro Ohe
Journal: Journal of Clinical Oncology (2014)

7597 Background: Patients with small-cell lung cancer (SCLC) that progress after first-line therapy have a dismal prognosis. Second-line chemotherapy is effective for some patients, but there is little evidence for third-line chemotherapy. The purpose of this study is to evaluate the efficacy of third-line chemotherapy and clarify prognostic factors for patients receiving it. Methods: Between November 2001 and October 2011, 202 of 648 patients who were consecutively diagnosed with SCLC at the National Cancer Center Hospital East received third-line chemotherapy. We performed multivariate Cox regression analysis to identify the prognostic factors of overall survival after third-line chemotherapy (OS). Results: At the start of third-line chemotherapy, median age was 66 years (range 38-83), male/ female: 168/34, ECOG performance status (PS) 0/1/2/3: 22/122/49/9, stage at diagnosis LD/ED: 88/114, response to second-line chemotherapy CR/PR/SD/PD: 3/95/56/48, and median progression free survival after second-line chemotherapy (PFS2) : 4.4 months. 155 and 47 patients received single-agent and platinum-based regimen, respectively. Overall response rate was 17.8%, which was significantly associated with response (CR/PR) to second-line chemotherapy (23.5% vs. 12.5%, p=0.042) and PFS2 (25.6% vs. 7.4%, p=0.024). Median PFS and OS from third-line chemotherapy were 2.7 months and 5.1 months, respectively. Multivariate Cox analysis identified PS 0-1 (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27-0.55; p < 0.001) and PFS2 ≥5 months (HR, 0.59; 95%CI, 0.42-0.81; p=0.001) were the independent prognostic factors indicating better OS. An optimal threshold of 5 months of PFS2 (≥5/<5 months: 82/120) was selected based on the concordance index adjusted by PS. Conclusions: PS 0-1 and PFS2 ≥5 months were associated with favorable prognosis among SCLC patients receiving third-line chemotherapy. These two factors would be worth considering as stratification factors when conducting future clinical trials.
Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.
Authors: Evangelos Terpos, Deborah Heath, Amin Rahemtulla, Kostas Zervas, Andrew Chantry, Athanasios Anagnostopoulos, Anastasia Pouli, Eirini Katodritou, Evgenia Verrou, Elisavet C. Vervessou, Meletios A. Dimopoulos, Peter Croucher
Journal: Blood (2006)
Low-dose metronomic chemotherapy in metastatic breast cancer: A retrospective analysis of 40 patients.
Authors: Mirela Souto, Andrea Shimada, Caroline Chaul Barbosa, Manuel Cruz Abrahao, Artur Katz
Journal: Journal of Clinical Oncology (2015)

e11567 Background: Low-dose metronomic chemotherapy is an emergent treatment schedule in which low doses of cytotoxic agents are given orally continuously, with no or short drug-free intervals. In general it provides better tolerance, especially in patients who have been previously exposed to other oncologic treatments. It is well known that all these low-dose schedules have a favorable safety profile and may provide an adequate tumor control in patients with metastatic breast cancer. However, there are no data in literature reporting the patient´s tolerance and response to subsequent lines of chemotherapy after receiving metronomic regimens. Methods: We retrospectively analyzed 40 patients with metastatic breast cancer treated with low doses of Cyclophosphamide and/or Methotrexate and/or Capecitabine in a single center from June 2009 to April 2014. The following data were collected: age, hormone and epidermal growth factor receptor 2 (HER-2) status, number of lines of chemotherapy prior to and after low-dose metronomic treatment, duration of metronomic treatment, toxicity reason for treatment discontinuation. Duration of low-dose metronomic chemotherapy was also correlated with the variables analyzed and treatment outcomes. Results: The median time on metronomic chemotherapy was 5.4 months. The most frequent drugs administered were cyclophosphamide, methotrexate and capecitabine alone. Asthenia, myelotoxicity, gastrintestinal symptoms and hand-foot syndrome were the most commonly recorded treatment related toxicity. Twenty six (65%) patients had the opportunity to go on to receive a classic chemotherapy regimen following metronomic regimen interruption. Although patients who developed toxicity to low-dose metronomic chemotherapy remained less time ( < 6 months) in subsequent chemotherapy, there was no statistically significant difference among those who received more lines of chemotherapy. Conclusions: Several patients received as many as three lines of additional chemotherapy for periods that exceeded 6 months of treatment, which suggests that the use of prolonged metronomic treatment does not affect a patient’s ability to tolerate subsequent therapy.
MODIFIED HEART SCORE IMPROVES EARLY, SAFE DISCHARGE FOR SUSPECTED ACUTE CORONARY SYNDROMES: A PROSPECTIVE COHORT STUDY WITH RECALIBRATION OF RISK SCORES TO UNDETECTABLE HIGH SENSITIVITY TROPONIN T LIMITS
Authors: Aleem Khand, Freddy Frost, Pei Chew, Michael Fisher, Liam Mullen, Ruth Grainger, Khaled Albouaini, Heidar Zadeh, Sarah Tong, James Dodd
Journal: Journal of the American College of Cardiology (2017)
5-YEAR OUTCOMES OF A STAGED HYBRID SURGICAL AND CATHETER-BASED ABLATION APPROACH FOR TREATMENT OF LONG-STANDING PERSISTENT ATRIAL FIBRILLATION
Authors: Arash Aryana, Stephen Stark, Deep Pujara, Genevieve Painter, Thomas M. Tadros, Subramaniam Krishnan, James Longoria
Journal: Journal of the American College of Cardiology (2017)
Multi-Center Study of Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Extra-Nodal Natural Killer/T-Cell Lymphoma, Nasal Type (ENKL)
Authors: Jonathan E. Brammer, Michelle Poon, Liang Piu Koh, Paolo F. Caimi, Marcos De Lima, Celina Ledesma, William Dibb, Issa F. Khouri, Yasuhiro Oki, Michelle A. Fanale, Richard E. Champlin, Richard T. Maziarz, Chitra M. Hosing
Journal: Blood (2015)
Assessment of quality of life (QOL) in melanoma patients: A systematic review of the literature
Authors: L. N. Davidson, Y. Xing, M. I. Ross, J. N. Cormier
Journal: Journal of Clinical Oncology (2004)

8211 Background:Because of the increase in incidence and the early age of onset, melanoma has emerged as an important public health problem. Among all cancer patients, quality of life (QOL) has repeatedly been shown to be an independent predictor of survival and response to therapy. A systematic review was performed to examine QOL instruments utilized in melanoma patients. Methods:A comprehensive literature search was performed in Medline (1966–2003), Current Contents, Cancerlit, and Cochrane Library using search terms related to QOL and melanoma. The results were supplemented by hand searching and cross-referencing. Selection criteria included: publications in English language journals, study population with a majority of melanoma patients; and measures of QOL as a primary or secondary objective. Raw data were extracted and categorized by study design. Study populations, instruments utilized, domains evaluated, and QOL results were summarized. Results:52 published reports were identified; 26 met inclusion criteria. Study designs included 6 prospective cohort studies, 7 clinical trials, and 13 cross-sectional studies. QOL endpoints were the primary objective in 19 studies. Eight instruments were used to measure overall QOL; 35 instruments were used to measure individual domains. Anxiety, depression, stress, and distress, which are prevalent among all cancer patients, were identified. Additionally, patients with early stage melanoma noted distress with regard to visible surgical scarring. With late stage melanoma, there was a notable deterioration in physical well-being (fatigue) and psychological adjustment (isolation and lack of independence). Treatment related differences were identified in overall QOL for patients receiving high-dose interferon and biochemotherapy. Heterogeneity of the studies' precluded a comprehensive statistical analysis. Conclusions:Given the lack of consistency, it is difficult to interpret published QOL results in melanoma patients. This analysis indicates that there is an overwhelming need for a melanoma-specific instrument to reliably assess QOL in future melanoma treatment trials. No significant financial relationships to disclose.
The Bone Morphogenetic Protein (BMP)-4 Is Involved in the Regulation of Human Megakaryocytic Differentiation during Thrombopoietin Signaling.
Authors: Franck E Nicolini, Sandrine Jeanpierre, Bastien Kaniewski, Charles Dumontet, Ruth Rimokh, Alain Puisieux, Véronique Maguer-Satta
Journal: Blood (2008)
MULTICENTER TRIAL OF A TRANSFEMORAL SYSTEM FOR MITRAL VALVE ANNULOPLASTY: UP-TO-2-YEAR FOLLOW-UP RESULTS
Authors: Karl-Heinz Kuck, Antonio Colombo, Ottavio Alfieri, Alec Vahanian, Stephan Baldus, Georg Nickenig, Francesco Maisano, Ralph Stephan Von Bardeleben, Jan van der Heyden, Joerg Hausleiter, Arthur Kerner, Corrado Tamburino
Journal: Journal of the American College of Cardiology (2017)
Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results
Authors: Liubov Polushkina, Irina Martynkevich, Vasily Shuvaev, Mikhail Fominykh, Dzhariyat Shikhbabaeva, Ekaterina Motyko, Lyudmila Martynenko, Natalya Cybakova, Marina Ivanova, Elena Shabanova, Anastasya Zhernyakova, Alsu Savrilova, Kudrat Abdulkadyrov
Journal: Blood (2016)
PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS: FROM INADEQUATE TO OVER-PROPHYLAXIS
Authors: Rahul Chaudhary, Martin Sanchez, Bhavina Batukbhai, Malini Chandra Serharan, Eric Feng, Charles R. Albrecht, Mauro Moscucci
Journal: Journal of the American College of Cardiology (2017)
MILD HYPOTHERMIA IN CARDIOGENIC SHOCK COMPLICATING MYOCARDIAL INFARCTION: THE RANDOMIZED SHOCK-COOL PILOT TRIAL
Authors: Georg Fuernau, Johannes Beck, Steffen Desch, Ingo Eitel, Christian Jung, Sandra Erbs, Norman Mangner, Karl Fengler, Marcus Sandri, Gerhard Schuler, Holger Thiele
Journal: Journal of the American College of Cardiology (2017)
AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.
Authors: Daniel Brigham, Barbara A. Belli, Michael Breider, Shripad Bhagwat, Wendell Wierenga, Robert C Armstrong
Journal: Blood (2009)
INTERLEUKIN 18 IMPAIRS EXCITATION CONTRACTION COUPLING IN CARDIOMYOCYTES AND PREDICTS MORTALITY IN ACUTE DECOMPENSATED HEART FAILURE
Authors: Elena Gonzalez, Judith Bernal-Ramirez, Andrea Cordero-Reyes, Jerry D. Estep, Keith Youker, García-Rivas Gerardo, Guillermo Torre-Amione, Catedra de Cardiologia
Journal: Journal of the American College of Cardiology (2017)
TRENDS AND IN-HOSPITAL OUTCOMES OF PATIENTS ADMITTED WITH ST ELEVATION MYOCARDIAL INFARCTION AND CHRONIC TOTAL OCCLUSIONS: INSIGHTS FROM A NATIONAL DATABASE
Authors: Nirmanmoh Bhatia, Sahil Agrawal, Arash Nayeri, Divyanshu Mohananey, Pedro Villablanca, Manyoo Agarwal, Lohit Garg, Elias Haddad
Journal: Journal of the American College of Cardiology (2017)
Trends in antidepressant prescribing at a comprehensive cancer center
Authors: M. J. Fisch, L. K. Sherman, A. T. Adamus, F. C. Hung, L. F. Shen, G. O. Lange, J. L. Palmer
Journal: Journal of Clinical Oncology (2004)

6132 Background: Antidepressant (AD) therapy may be initiated in cancer patients for affective or anxiety disorders, or management of symptoms. Practice patterns vary, and prescribing trends are poorly understood. Methods: Retrospective cohort study using outpatient prescribing data and routine clinical data available through the computerized data system at our comprehensive cancer center (CC). Results: Whereas the CC patient population “at risk” for AD exposure increased by 19% between 1998 and 2001( from 46, 081 to 54,902 patients), there was a 37% increase in the number of patients who filled an AD prescription at the CC pharmacy (p<0.0001). In the AD cohort of 2001, there was a preponderance of women (58.5%) and Caucasian (76%) patients and 65.5% were in the 40–65 yr. age category. Also noted was a significant association between gender and race (p<0.0001) in this group. Only 34.6% had an ICD-9 coded diagnosis related to depression or anxiety, and 246/1782 (13.8%) of patients were prescribed an AD by a psychiatrist. Patients with AD from psychiatrists had a higher median yearly total AD cost ($203.52 vs. $72.49, p<0.00001), and more physician visits per year (median 13.5 vs. 10.0, p<0.00001). When considering the larger cohort of 4,841 patients who received an opioid and/or an AD prescription in 2001, the odds of receiving an AD were significantly increased in women, even adjusting for age-category and race (odds ratio 1.60, 95% CI 1.42–1.81). Finally, the category of AD prescribed shifted between 1998–2001 away from tricyclics (TCA) towards serotonin-reuptake inhibitors (SSRI) and other newer AD (p<0.0001). Conclusions: AD prescribing is increasing at our CC and women are more likely to receive an AD. Most AD are prescribed by non-psychiatrists and without a coded diagnosis related to depression or anxiety. There is increasing use of newer antidepressants, and psychiatrists have unique prescribing trends at our CC. No significant financial relationships to disclose.
Comparing true tumor volume to unidimensional and bidimensional measurements in lung cancer—A better discriminator of response?
Authors: L. H. Schwartz, B. Zhao, C. Moskowitz, G. Michelle, N. A. Rizvi, M. G. Kris
Journal: Journal of Clinical Oncology (2006)

13020 Background: Accurate evaluation of response is crucial to determine if a treatment is effective for a particular patient or if an experimental agent is effective against a specific tumor type. Current measurement techniques such as WHO and RECIST are limited by only identifying changes in size in the axial plane, and with one or two dimensions. We devised and tested a semi-automated algorithm to calculate tumor volume and other parameters on thin-section CT scans to assess response in patients with non-small cell lung cancer (NSCLC) treated with gefitinib in a clinical trial. Methods: CT scans of 15 measurable pre- and post-gefitinib-treated non-small-cell lung cancers in 15 patients were analyzed. A semi-automated three-dimensional segmentation algorithm was developed for lung cancer and applied to each tumor at baseline and follow-up. The computer automatically identified the boundaries of the tumors in three dimensions and the “true” volume and calculated the greatest diameter and the product of the greatest diameter and its perpendicular. Exact McNemar tests were used to analyze differences between RECIST, WHO and volumetric changes from baseline to follow up. Results: The computer accurately segmented 14 of 15 tumors. One paramediastinal tumor required manual separation from the mediastinum. Seventy-three percent (11/15) of patients had an absolute change of at least 20% in tumor volume, compared with 7% (1/15) and 27% (4/15) with similar changes in uni-dimensional (p &lt; 0.01) and bi-dimensional (p = 0.04) tumor measurements, respectively. Forty-seven percent (7/15) of patients had an absolute change of at least 30% in tumor volume, but an absolute change of at least 30% was found in no patients by uni-dimensional measurement (p = 0.02) and in 13% of patients by bi-dimensional measurement (p = 0.06). Analysis of percentage change using an adjusted/scaled method will also be presented. Conclusions: By measuring tumor volume, greater numbers of patients were identified having absolute changes of at least 20% and 30% than by using RECIST or WHO. Therefore, volumetric changes may have the potential to be an earlier or better marker of regression or progression. No significant financial relationships to disclose.
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
Authors: Paul Gerard Guy Richardson, Craig C. Hofmeister, David Samuel DiCapua Siegel, Sagar Lonial, Jacob Laubach, Yvonne Adeduni Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Noopur S. Raje, Mohamed H. Zaki, Ye Hua, Sheetal Shah, Jianming Wang, Kenneth Carl Anderson
Journal: Journal of Clinical Oncology (2013)

8584 Background: Combinations of lenalidomide (LEN), bortezomib (BORT), and dexamethasone (DEX) have demonstrated preclinical and clinical activity in patients (pts) with multiple myeloma. Pomalidomide with low-dose DEX (LoDEX) has demonstrated efficacy in RRMM pts treated with prior LEN and BORT. MM-005 was designed to identify the optimal PVD dose for a phase 3 trial comparing PVD vs BORT + LoDEX (VD) in RRMM (MM-007). Methods: Eligible pts had RRMM with 1-4 prior therapies including ≥ 2 consecutive cycles of LEN and a proteasome inhibitor. Pts must have been refractory to LEN (progressive disease [PD] during or within 60 days of LEN treatment), but not refractory to BORT (at 1.3 mg/m 2 twice-weekly). The maximum tolerated dose (MTD) was determined using a 3 + 3 design in 5 cohorts. Each cohort received 21-day cycles of POM 1-4mg/day on D1-14; BORT 1-1.3mg/m 2 on D1, 4, 8, 11; and LoDEX 20mg/day on D1-2, 4-5, 8-9, 11-12. An expansion cohort was enrolled at the MTD. Treatment was continued until PD or unacceptable toxicity. Dose-limiting toxicities (DLTs) were assessed during cycle 1. The primary endpoint was MTD; secondary endpoints were safety, overall response rate (ORR; ≥ partial response), duration of response, and time to response (TTR). Results: As of Dec 31, 2012, 21 pts were enrolled (3 pts per escalating dose cohort; 6 in the expansion cohort). Median age was 57 years (36-75). All were LEN-refractory and had prior BORT. No DLTs were observed at any dose level. The most common grade 3/4 adverse events (AEs) were neutropenia (32%) and thrombocytopenia (21%). With thromboprophylaxis, no deep vein thrombosis was observed. 17 pts remain on study and no pts have discontinued treatment due to AE. Thus far, the ORR was 72% (n = 18 evaluable) and responses were rapid (median TTR, 2 cycles). Conclusions: PVD was well-tolerated in RRMM with no DLTs and no discontinuations due to AE to date. PVD has promising activity with a current ORR of 72%. The maximum planned dose of POM 4mg/day on D1-14; BORT 1.3mg/m 2 on D1, 4, 8, and 11; and DEX 20mg on D1-2, 4-5, 8-9, 11-12 of a 21-day cycle has now been incorporated into the MM-007 phase III trial comparing PVD with VD in RRMM pts (N = 782 planned). Clinical trial information: NCT01497093.
LEFT VENTRICULAR TORSION SHEAR ANGLE VOLUME APPROACH FOR NON-INVASIVE EVALUATION OF DIASTOLIC DYSFUNCTION IN PRESERVED EJECTION FRACTION
Authors: Himanshu Gupta, Oleg F. Sharifov, Chun S. Schiros, Inmaculada Aban, Gilbert Perry, Louis J. Dell'italia, Thomas Denney
Journal: Journal of the American College of Cardiology (2017)
Disruption of the ATXN1–CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans
Authors: Hsiang-Chih Lu, Qiumin Tan, Maxime W C Rousseaux, Wei Wang, Ji-Yoen Kim, Ronald Richman, Ying-Wooi Wan, Szu-Ying Yeh, Jay M Patel, Xiuyun Liu, Tao Lin, Yoontae Lee, John D Fryer, Jing Han, Maria Chahrour, Richard H Finnell, Yunping Lei, Maria E Zurita-Jimenez, Priyanka Ahimaz, Kwame Anyane-Yeboa, Lionel Van Maldergem, Daphne Lehalle, Nolwenn Jean-Marcais, Anne-Laure Mosca-Boidron, Julien Thevenon, Margot A Cousin, Della E Bro, Brendan C Lanpher, Eric W Klee, Nora Alexander, Matthew N Bainbridge, Harry T Orr, Roy V Sillitoe, M Cecilia Ljungberg, Zhandong Liu, Christian P Schaaf, Huda Y Zoghbi
Journal: Nature Genetics (2017)
VENTRICULAR SEPTAL DISSECTION WITH RUPTURE AND LARGE NEOCAVITY AFTER INFERIOR ST ELEVATION MYOCARDIAL INFARCTION IN A PATIENT WITH RECENT CORONARY ARTERY BYPASS GRAFTS
Authors: Juan Mendieta Hernandez, Mit Patel, Quinn Pack, Amir Lotfi, Leng Jiang
Journal: Journal of the American College of Cardiology (2017)
Cancer screening in France: 3rd edition of the EDIFICE survey.
Authors: Jérôme Viguier, Francois Eisinger, Yvan Coscas, Jean F. Morere, Jean-Yves Blay, Claire Roussel, Xavier B. Pivot
Journal: Journal of Clinical Oncology (2012)

1568 Background: The EDIFICE survey program started in 2005 and was aimed at providing a better understanding of the participation of the French population in cancer screening programs and assess the evolution over time. The EDIFICE 3 survey was conducted in 2011, following EDIFICE 1 (2005) and EDIFICE 2 (2008), and focused on colorectal, breast and prostate cancer. Methods: This third nationwide observational study, EDIFICE 3, was conducted by phone interviews among a representative sample of 1603 subjects aged between 40 and 75 years, using the quota method. The analysis focused on the target population of the national screening programs for breast and colorectal cancer (50-74 years). The same population was analysed for prostate cancer screening behaviours. Results: For breast cancer, the rate of women attending at least one screening test was 93%/94%/95% in 2005/2008/2011 respectively. A mammography had been performed as recommended within the last two years for 75%/83%/83% among them. We observed an increase in timing compliance between 2005 and 2011, significant for women aged 65-74. For colorectal cancer, the rate of subjects attending at least one screening test was 25%/38%/59%. A fecal test or colonoscopy had been performed according to the recommended timing for NA/30%/51% among them. Colorectal cancer screening has increased significantly in all age groups, especially between 65 and 69 years, and for both genders. For prostate cancer, the rate of men having performed at least one screening test (PSA and/or rectal examination) was 36%/49%/50%.This rate have significantly decreased in men aged 50-59 between 2008 and 2011(44% vs 37%, p&lt;0.05). Conclusions: For National Programs, the attendance rate remains high for breast cancer screening and is improving for colorectal cancer screening. However, the European guideline objective rate of participation for colorectal cancer screening has not yet been reached. Despite the absence of recommendations, prostate cancer screening is frequently carried out and stable overall.
Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI
Authors: Matthias Götberg, Evald H. Christiansen, Ingibjörg J. Gudmundsdottir, Lennart Sandhall, Mikael Danielewicz, Lars Jakobsen, Sven-Erik Olsson, Patrik Öhagen, Hans Olsson, Elmir Omerovic, Fredrik Calais, Pontus Lindroos, Michael Maeng, Tim Tödt, Dimitrios Venetsanos, Stefan K. James, Amra Kåregren, Margareta Nilsson, Jörg Carlsson, Dario Hauer, Jens Jensen, Ann-Charlotte Karlsson, Georgios Panayi, David Erlinge, Ole Fröbert
Journal: New England Journal of Medicine (2017)

The instantaneous wave-free ratio (iFR) is an index used to assess the severity of coronary-artery stenosis. The index has been tested against fractional flow reserve (FFR) in small trials, and the two measures have been found to have similar diagnostic accuracy. However, studies of clinical outcomes associated with the use of iFR are lacking. We aimed to evaluate whether iFR is noninferior to FFR with respect to the rate of subsequent major adverse cardiac events.
TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)
Authors: Roman Galetto, Céline Lebuhotel, Agnès Gouble, Nuria Mencia-Trinchant, Cruz M Nicole, Gail J. Roboz, Monica L. Guzman, Julianne Smith
Journal: Blood (2015)